China's New Drug Price Policies Will Favor Big Distributors, Restrict Smaller Ones
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China is releasing a series of new policies to fight bribery in the pharmaceutical industry and reduce drug prices, which will benefit large distributors such as SinoPharm, Shanghai Pharmaceutical Group and Jointown, said an expert in a Citi research conference call July 19
You may also be interested in...
Dance With Domestic Companies: Pfizer And Merck Look To Broaden Market Access In China Via JVs
Merck/Simcere, Pfizer/Hisun launched JVs in China this week to increase sales in outlying cities.
Dance With Domestic Companies: Pfizer And Merck Look To Broaden Market Access In China Via JVs
Merck/Simcere, Pfizer/Hisun launched JVs in China this week to increase sales in outlying cities.
Cardinal Health's Acquisition Of Zuellig Pharma Signal Of China's Intent To Allow More Foreign Investment?
SHANGHAI - In what some are calling a transformational event for the China pharma industry, Cardinal Health announced Nov. 29 that it has closed a deal to acquire local private distributor Zuellig Pharma China (Yong Yu in Chinese) for $470 million